ADC Therapeutics has been granted a patent for a method of treating cancer and autoimmune diseases using CD19-antibody drug conjugates (ADCs) with a specific drug to antibody ratio. The treatment involves multiple cycles with reduced dosage, targeting CD19+ diseases. GlobalData’s report on ADC Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ADC Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. ADC Therapeutics's grant share as of April 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cd19+ cancer or autoimmune disease with cd19-adcs
A recently granted patent (Publication Number: US11938192B2) discloses a method for treating subjects with proliferative diseases, specifically CD19+ cancers or autoimmune diseases. The method involves administering a CD19-antibody drug conjugate (ADC) with a pyrrolobenzodiazepine (PBD) dimer linked to an antibody binding to CD19. The CD19-ADC is given in a dosage regime comprising at least two treatment cycles, with a reduction in dose after the second cycle. The patent specifies a drug to antibody ratio (DAR) of 1 to 8 and includes the option of combining the CD19-ADC with a steroid for enhanced efficacy.
Furthermore, the patent outlines specific details regarding the structure of the CD19-ADC, including the amino acid sequences of the antibody domains and the chemical structure of the PBD dimer. It also provides precise dosage information, suggesting a starting dose range of 121 µg/kg to 180 µg/kg, with a recommended starting dose of 140 µg/kg to 160 µg/kg. The method allows for flexibility in treatment cycles, with options for 3-week or 6-week cycles, and emphasizes the importance of dose reduction post the second cycle for optimal therapeutic outcomes. Additionally, the patent highlights the potential application of this method in treating various CD19+ proliferative diseases, such as leukemia, lymphoma, and CD19+ overexpressing cancers, offering a tailored approach to addressing these conditions.
To know more about GlobalData’s detailed insights on ADC Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
